Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
ObjectivesTo review neurological complications after the influenza A (H1N1) pdm09, highlighting the clinical differences between patients with post-vaccine or viral infection.DesignA search on Medline, Ovid, EMBASE, and PubMed databases using the keywords “neurological complications of Influenza AH1N1” or “post-vaccine Influenza AH1N1.”SettingOnly papers written in English, Spanish, German, French, Portuguese, and Italian published from March 2009 to December 2012 were included.SampleWe included 104 articles presenting a total of 1636 patient cases. In addition, two cases of influenza vaccine-related neurological events from our neurological care center, arising during the period of study, were also included.Main outcome measuresDemographic data and clinical diagnosis of neurological complications and outcomes: death, neurological sequelae or recovery after influenza A (H1N1) pdm09 vaccine or infection.ResultsThe retrieved cases were divided into two groups: the post-vaccination group, with 287 patients, and the viral infection group, with 1349 patients. Most patients in the first group were adults. The main neurological complications were Guillain-Barre syndrome (GBS) or polyneuropathy (125), and seizures (23). All patients survived. Pediatric patients were predominant in the viral infection group. In this group, 60 patients (4.7%) died and 52 (30.1%) developed permanent sequelae. A wide spectrum of neurological complications was observed.ConclusionsFatal cases and severe, permanent, neurological sequelae were observed in the infection group only. Clinical outcome was more favorable in the post-vaccination group. In this context, the relevance of an accurate neurological evaluation is demonstrated for all suspicious cases, as well as the need of an appropriate long-term clinical and imaging follow-up of infection and post-vaccination events related to influenza A (H1N1) pdm09, to clearly estimate the magnitude of neurological complications leading to permanent disability.
ObjectivesTo review neurological complications after the influenza A (H1N1) pdm09, highlighting the clinical differences between patients with post-vaccine or viral infection.DesignA search on Medline, Ovid, EMBASE, and PubMed databases using the keywords “neurological complications of Influenza AH1N1” or “post-vaccine Influenza AH1N1.”SettingOnly papers written in English, Spanish, German, French, Portuguese, and Italian published from March 2009 to December 2012 were included.SampleWe included 104 articles presenting a total of 1636 patient cases. In addition, two cases of influenza vaccine-related neurological events from our neurological care center, arising during the period of study, were also included.Main outcome measuresDemographic data and clinical diagnosis of neurological complications and outcomes: death, neurological sequelae or recovery after influenza A (H1N1) pdm09 vaccine or infection.ResultsThe retrieved cases were divided into two groups: the post-vaccination group, with 287 patients, and the viral infection group, with 1349 patients. Most patients in the first group were adults. The main neurological complications were Guillain-Barre syndrome (GBS) or polyneuropathy (125), and seizures (23). All patients survived. Pediatric patients were predominant in the viral infection group. In this group, 60 patients (4.7%) died and 52 (30.1%) developed permanent sequelae. A wide spectrum of neurological complications was observed.ConclusionsFatal cases and severe, permanent, neurological sequelae were observed in the infection group only. Clinical outcome was more favorable in the post-vaccination group. In this context, the relevance of an accurate neurological evaluation is demonstrated for all suspicious cases, as well as the need of an appropriate long-term clinical and imaging follow-up of infection and post-vaccination events related to influenza A (H1N1) pdm09, to clearly estimate the magnitude of neurological complications leading to permanent disability.
Myocarditis is defined as an inflammation of myocardium where the infiltrating leukocytes are intimately associated with cardiomyocyte necrosis or drop-out (Liu, 2005; Woodruff, 1980). Cardiac damage may be minimal and self-limiting or may result in chronic fibrosis and cardiac dysfunction leading to death in children and young adults (Eckart et al., 2004; Fabre, 2006; Solberg et al., 2010). As discussed in other chapters of this book, infections with a highly diverse group of viruses, bacteria, fungi, and worms have been implicated in infectious myocarditis (Friman et al., 1995). Enteroviruses and adenoviruses are usually considered as the predominant viral etiological agents, and are associated with approximately 80% of clinical myocarditis where a viral infection is documented. However, virtually any virus infection may initiate myocarditis (Bowles et al., 2003; Woodruff, 1980). While seasonal influenza virus is only a minor etiological agent in myocarditis, evidence from the most recent influenza H1N1 pandemic (Vila de Muga et al., 2010; Wiegand et al., 2010; Zheng et al., 2010) suggests a higher incidence of both mortality and morbidity, and accounts for 5% of complications in infected children (Zheng et al., 2010). Myocardial injury results either directly from replication and induction of death or dysfunction in infected cardiocytes, or from host responses to infection (Huber, 2010). Although anti-viral host responses (innate or adaptive) are intended to control and eliminate the infection, cytokines and by-products such as nitric oxide or oxygen free radicals may also damage adjacent uninfected cells (Szalay et al., 2006). Innate immunity is the initial host response to infection and usually occurs within hours or days of virus introduction. The major characteristic of the innate response, besides its rapidity, is that it is broadly reactive to multiple infectious agents. While it is highly unlikely that innate immunity can completely eliminate the infection, it can suppress microbial replication until the far more potent and highly specific adaptive immune response kicks in. The reason for this is quite simple, viruses replicate rapidly with, for example, one picornavirus infected cell in tissue culture producing up to a million progeny virions within 18-24 hrs. In vivo, such rapid and uncontrolled growth could result in extensive tissue injury or death of the organism prior to a useful adaptive immune response being established since during a primary immune response, production of meaningful numbers of virus-specific T cells could www.intechopen.com Myocarditis 218 take 7-10 days after virus inoculation. The best known innate immunity results from microbial products binding to and activating Toll-Like Receptors (TLR) or RNA helicases (RIG-I and MDA-5) which activate transcription factors (NFkB) leading to expression of cytokines (TNF , IL-1 and IL-6) and nitric oxide (Hosoi et al., 2004; Michelsen et al., 2004); or interferon response factors (IRF3/7) leading to expression of type 1 interferons (IFN /) ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.